AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31874733 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued usual cricket activity)
Number of subjects: 65
Study 30613990 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine (4.3 log plaque-forming unit)
Number of subjects: 0
Study 30613990 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine (4.7 log plaque-forming unit)
Number of subjects: 0
Study 30613990 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine (4.9 log plaque-forming unit)
Number of subjects: 0
Study 30613990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28400181 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 24
Study 28400181 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 24
Study 25407688 — intervention group
Group type: EXPERIMENTAL
Intervention: Zen meditation (MG) - meditated twice a day for 20 minutes for 3 months
Number of subjects: 59
Study 25407688 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - remained on a waiting list
Number of subjects: 59
Study 25407688 — intervention group
Group type: EXPERIMENTAL
Intervention: Zen meditation (MG)
Number of subjects: 59
Study 25407688 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 59
Study 24197403 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine follow-up
Number of subjects: 359
Study 24197403 — intervention group
Group type: COMPARATOR
Intervention: Control group (in-clinic follow-up only)
Number of subjects: 359
Study 24197403 — intervention group
Group type: COMPARATOR
Intervention: Comparison of pacemaker replacements
Number of subjects: 359
Study 24197403 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient outcomes
Number of subjects: 359
Study 21353462 — intervention group
Group type: EXPERIMENTAL
Intervention: Williams syndrome (WS) subjects
Number of subjects: 0
Study 21353462 — intervention group
Group type: COMPARATOR
Intervention: Mental age‐matched control children
Number of subjects: 0
Study 19692317 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical BCG treatment (81 mg for 6 weeks)
Number of subjects: 41
Study 17206567 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy after partial duodenopancreatectomy
Number of subjects: 0
Study 17206567 — intervention group
Group type: COMPARATOR
Intervention: Standard lymphadenectomy
Number of subjects: 0
Study 17206567 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy
Number of subjects: 0
Study 14687272 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive frame video
Number of subjects: 179
Study 14687272 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral frame video
Number of subjects: 179
Study 14687272 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative frame video
Number of subjects: 179
Study 10755174 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 5
Study 10755174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 9332992 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic saline amnioinfusion
Number of subjects: 0
Study 9332992 — intervention group
Group type: COMPARATOR
Intervention: Control cases (no amnioinfusion)
Number of subjects: 0
Study 8223740 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (0.25 mg and 0.50 mg)
Number of subjects: 8
Study 2880458 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxypertine
Number of subjects: 0
Study 2880458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31054038 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance Spectroscopy (BIS)
Number of subjects: 508
Study 31054038 — intervention group
Group type: COMPARATOR
Intervention: Tape Measurement (TM)
Number of subjects: 508
Study 29713909 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (600 mg/day)
Number of subjects: 16
Study 29713909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 27435761 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 1500 mg/daily continuously with rabeprazole 1.5 mg/kg twice a day, 3 days a week
Number of subjects: 66
Study 27435761 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine 1500 mg/daily continuously without rabeprazole
Number of subjects: 66
Study 24666633 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers In Motion (MIM) intervention group
Number of subjects: 525
Study 24666633 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (printed educational materials)
Number of subjects: 525
Study 23291025 — intervention group
Group type: EXPERIMENTAL
Intervention: Early continuous high-volume-hemofiltration
Number of subjects: 60
Study 20118792 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (continuous administration during anesthesia)
Number of subjects: 56
Study 20118792 — intervention group
Group type: COMPARATOR
Intervention: Control (no landiolol except bolus for uncontrolled tachycardia)
Number of subjects: 56
Study 18590431 — intervention group
Group type: EXPERIMENTAL
Intervention: Skull block with 0.5% ropivacaine
Number of subjects: 30
Study 18590431 — intervention group
Group type: COMPARATOR
Intervention: Control (no skull block)
Number of subjects: 30
Study 15676092 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia therapy (n=20)
Number of subjects: 40
Study 15676092 — intervention group
Group type: COMPARATOR
Intervention: Normothermia therapy (n=20)
Number of subjects: 40
Study 11846857 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg twice/day for 6 days along with 0.4 mg digoxin on study day 5
Number of subjects: 12
Study 11846857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12132546 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher death distress
Number of subjects: 70
Study 12132546 — intervention group
Group type: EXPERIMENTAL
Intervention: Death distress
Number of subjects: 70
Study 12132546 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial-spiritual dimensions
Number of subjects: 70
Study 9893777 — intervention group
Group type: EXPERIMENTAL
Intervention: Early extubation (Group A) with mechanical ventilatory support for 4‐7 h
Number of subjects: 144
Study 9893777 — intervention group
Group type: COMPARATOR
Intervention: Routine extubation (Group B) with mechanical ventilatory support for 8‐14 h
Number of subjects: 144
Study 8279616 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual skin screening by a dermatologist and education session; n = 65
Number of subjects: 142
Study 8279616 — intervention group
Group type: COMPARATOR
Intervention: Control group; n = 77
Number of subjects: 142
Study 8279616 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups improved in knowledge score; n = 142
Number of subjects: 142
Study 8279616 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups; n = 142
Number of subjects: 142
Study 2500401 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil
Number of subjects: 36
Study 2500401 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 36
Study 31104039 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored and integrated violence prevention program in psychiatric wards and prisons
Number of subjects: 0
Study 28340244 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (150 mg/d for 7 days)
Number of subjects: 17
Study 28340244 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 7 days)
Number of subjects: 17
Study 25469804 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (target dose 16 mg/d)
Number of subjects: 51
Study 25469804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 23884659 — intervention group
Group type: EXPERIMENTAL
Intervention: CJ leflunomide 10 mg
Number of subjects: 56
Study 23884659 — intervention group
Group type: EXPERIMENTAL
Intervention: CJ leflunomide 20 mg
Number of subjects: 56
Study 23884659 — intervention group
Group type: COMPARATOR
Intervention: Arava® (reference drug)
Number of subjects: 56
Study 21149288 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia website
Number of subjects: 0
Study 21149288 — intervention group
Group type: COMPARATOR
Intervention: Existing brochure
Number of subjects: 0
Study 21149288 — intervention group
Group type: COMPARATOR
Intervention: Non-brochure and non-website users
Number of subjects: 0
Study 18243516 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined high-dosed antimuscarinics
Number of subjects: 27
Study 16870004 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot skimmed milk formulation (15 mg zeaxanthin)
Number of subjects: 12
Study 16870004 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm skimmed milk formulation (15 mg zeaxanthin)
Number of subjects: 12
Study 16870004 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water formulation (15 mg zeaxanthin)
Number of subjects: 12
Study 14768141 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic exploration
Number of subjects: 34
Study 14768141 — intervention group
Group type: COMPARATOR
Intervention: Open surgical exploration
Number of subjects: 34
Study 10851837 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of vitamin A
Number of subjects: 0
Study 10851837 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 9166880 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing therapy with videoendoscopic biofeedback
Number of subjects: 0
Study 9166880 — intervention group
Group type: COMPARATOR
Intervention: Conventional swallowing therapy
Number of subjects: 0
Study 8246577 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 0.3 microgram/kg
Number of subjects: 112
Study 8246577 — intervention group
Group type: COMPARATOR
Intervention: Saline solution placebo
Number of subjects: 112
Study 30476999 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar intermittent θ‐burst stimulation (CRB‐iTBS)
Number of subjects: 36
Study 30476999 — intervention group
Group type: COMPARATOR
Intervention: Sham iTBS
Number of subjects: 36
Study 29195573 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR with CoreValve bioprosthesis
Number of subjects: 797
Study 29195573 — intervention group
Group type: COMPARATOR
Intervention: SAVR with surgical bioprosthetic valve
Number of subjects: 797
Study 29195573 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 797
Study 29195573 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 797
Study 29195573 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TAVR and SAVR
Number of subjects: 797
Study 25978852 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg Folic Acid
Number of subjects: 622
Study 25978852 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 μg Folic Acid
Number of subjects: 622
Study 25978852 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g Creatine
Number of subjects: 622
Study 25978852 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g Creatine + 400 μg Folic Acid
Number of subjects: 622
Study 25978852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 622
Study 22984216 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored HIV prevention intervention (six group-based sessions and one individual session)
Number of subjects: 0
Study 22984216 — intervention group
Group type: COMPARATOR
Intervention: Control condition (single-session HIV prevention review)
Number of subjects: 0
Study 20433248 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal 3% prilocaine
Number of subjects: 32
Study 20433248 — intervention group
Group type: COMPARATOR
Intervention: 3% plain prilocaine
Number of subjects: 32
Study 20433248 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% prilocaine with 0.03IU/mL felypressin
Number of subjects: 32
Study 19939302 — intervention group
Group type: EXPERIMENTAL
Intervention: Life completion discussion intervention
Number of subjects: 18
Study 19939302 — intervention group
Group type: COMPARATOR
Intervention: Attention control (relaxation meditation)
Number of subjects: 18
Study 19939302 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 18
Study 16750464 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac ophthalmic suspension 0.03%
Number of subjects: 60
Study 16750464 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac ophthalmic suspension 0.1%
Number of subjects: 60
Study 16750464 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium ophthalmic solution 0.1%
Number of subjects: 60
Study 15142073 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaseline applied twice a day bilaterally for 4 weeks
Number of subjects: 105
Study 15142073 — intervention group
Group type: COMPARATOR
Intervention: Control group (simple observation with an 8-week appointment)
Number of subjects: 105
Study 11312048 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg morphine into inflamed submucous tissue
Number of subjects: 96
Study 11312048 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg morphine into non-inflamed tissue
Number of subjects: 96
Study 11312048 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg morphine perineurally
Number of subjects: 96
Study 11312048 — intervention group
Group type: COMPARATOR
Intervention: Control group (articaine plus saline) for inflamed tissue
Number of subjects: 96
Study 11312048 — intervention group
Group type: COMPARATOR
Intervention: Control group (articaine plus saline) for non-inflamed tissue
Number of subjects: 96
Study 11312048 — intervention group
Group type: COMPARATOR
Intervention: Control group (articaine plus saline) for perineural tissue
Number of subjects: 96
Study 9202804 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized furosemide (2 mg/kg)
Number of subjects: 8
Study 9202804 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 8
Study 8187026 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled phosphoramidon (10(-5) M)
Number of subjects: 6
Study 8187026 — intervention group
Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 6
Study 8187026 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled NKA
Number of subjects: 6
Study 3307881 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (100 micrograms b.i.d.)
Number of subjects: 21
Study 3307881 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (100 micrograms b.i.d.)
Number of subjects: 21
Study 3307881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 29454601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-linked polyethylene
Number of subjects: 25
Study 29454601 — intervention group
Group type: COMPARATOR
Intervention: Ultra-high molecular weight polyethylene (UHMWPE)
Number of subjects: 25
Study 29454601 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of inserts
Number of subjects: 25
Study 27666137 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer cement without heat application (HVGIC)
Number of subjects: 801
Study 27666137 — intervention group
Group type: EXPERIMENTAL
Intervention: LED thermocured high-viscosity glass-ionomer cement (HVGIC)
Number of subjects: 801
Study 27666137 — intervention group
Group type: COMPARATOR
Intervention: Composite resin
Number of subjects: 801
Study 25343850 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein/fibre preload (17 g whey protein, 3 g lactose, 5 g guar, 1 g flavour material in 150 ml cold water)
Number of subjects: 24
Study 25343850 — intervention group
Group type: COMPARATOR
Intervention: Control (150 ml cold water with no additives)
Number of subjects: 24
Study 23755872 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 hours of daily patching
Number of subjects: 169
Study 23755872 — intervention group
Group type: COMPARATOR
Intervention: 2 hours of daily patching
Number of subjects: 169
Study 20692161 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent Stroop condition with perturbed proprioceptive inputs
Number of subjects: 36
Study 20692161 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-congruent Stroop condition with perturbed proprioceptive inputs
Number of subjects: 36
Study 20692161 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent Stroop condition without perturbed proprioceptive inputs
Number of subjects: 36
Study 20692161 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-congruent Stroop condition without perturbed proprioceptive inputs
Number of subjects: 36
Study 18057088 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative inspiratory muscle training
Number of subjects: 20
Study 18057088 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 20
Study 16849865 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Evaluation and Management Unit (GEMU)
Number of subjects: 254
Study 16849865 — intervention group
Group type: COMPARATOR
Intervention: Medical Wards (MW)
Number of subjects: 254
Study 14682552 — intervention group
Group type: EXPERIMENTAL
Intervention: Slider shoe
Number of subjects: 4
Study 14682552 — intervention group
Group type: COMPARATOR
Intervention: Baseline phase (A1)
Number of subjects: 4
Study 11057391 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic mattress covers (polyester microfaser with polyurethane surface layer)
Number of subjects: 84
Study 11057391 — intervention group
Group type: COMPARATOR
Intervention: Cotton mattress covers
Number of subjects: 84
Study 9029898 — intervention group
Group type: COMPARATOR
Intervention: Mucinous adenocarcinoma (Group 1)
Number of subjects: 58
Study 1503519 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (hGH; 0.3 U/kg/24 hours)
Number of subjects: 17
Study 1503519 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study 6510453 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol (40 mg)
Number of subjects: 12
Study 6510453 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 12
Study 6510453 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release metoprolol (200 mg)
Number of subjects: 12
Study 6510453 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study 30616674 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected music
Number of subjects: 170
Study 30616674 — intervention group
Group type: COMPARATOR
Intervention: Predetermined music from MUSIC CARE®
Number of subjects: 170
Study 27770155 — intervention group
Group type: EXPERIMENTAL
Intervention: BMD fast track program with full fracture risk assessment
Number of subjects: 0
Study 27770155 — intervention group
Group type: EXPERIMENTAL
Intervention: BMD fast track program
Number of subjects: 0
Study 25781198 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine-based supplement (3.0 g of arginine, 300 mg of grape seed extract, and 300 mg of polyethylene glycol)
Number of subjects: 19
Study 25781198 — intervention group
Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 19
Study 25781198 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine-based supplement
Number of subjects: 19
Study 25781198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 25118795 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP (Tenofovir)
Number of subjects: 1785
Study 22351374 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral for CRC screening
Number of subjects: 159
Study 22351374 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of CRC screening
Number of subjects: 159
Study 22351374 — intervention group
Group type: EXPERIMENTAL
Intervention: Readiness to change
Number of subjects: 159
Study 22351374 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid conditions
Number of subjects: 159
Study 19542795 — intervention group
Group type: EXPERIMENTAL
Intervention: IVPCA morphine plus ketorolac (M+K group)
Number of subjects: 102
Study 19542795 — intervention group
Group type: COMPARATOR
Intervention: IVPCA morphine (M group)
Number of subjects: 102
Study 17337467 — intervention group
Group type: EXPERIMENTAL
Intervention: HP10 antigen detection ELISA applied to serum
Number of subjects: 116
Study 17337467 — intervention group
Group type: EXPERIMENTAL
Intervention: HP10 antigen detection ELISA applied to cerebrospinal fluid (CSF)
Number of subjects: 116
Study 17337467 — intervention group
Group type: EXPERIMENTAL
Intervention: HP10 antigen detection ELISA
Number of subjects: 116
Study 12510800 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg
Number of subjects: 437
Study 12510800 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 40 microg
Number of subjects: 437
Study 12510800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study 11020183 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional airway CT
Number of subjects: 50
Study 9049514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg b.d.
Number of subjects: 2006
Study 9049514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 2006
Study 9049514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2006
Study 9049514 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 2006
Study 8350705 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking group (exercised 30-40 min, 5 days/week for 12 weeks at 60% heart rate reserve)
Number of subjects: 32
Study 8350705 — intervention group
Group type: COMPARATOR
Intervention: Calisthenic group (engaged in mild range-of-motion and flexibility movements for 12 weeks)
Number of subjects: 32
Study 8350705 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly conditioned group (cross-sectional comparison)
Number of subjects: 32
Study 8350705 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking group
Number of subjects: 32
Study 3524550 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria tents
Number of subjects: 60
Study 3524550 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical PGF2 alpha gel
Number of subjects: 60
Study 3524550 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 60
Study 29684661 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU monthly)
Number of subjects: 2494
Study 29684661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2494